Table III.
Distribution of CYP3A5*3, CYP3A4*18 and CYP2B6*6 polymorphisms in chronic myeloid leukaemia patients with respect to epidemiological and clinical parameters
| Genotype | Age (yr) | Gender | Sokal risk score | CML stages | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||
| <50 (n-103), n (%) | ≥50 (n=51), n (%) | Male (n=74), n (%) | Female (n=79), n (%) | High (n=19), n (%) | Medium (n=87), n (%) | Low (n=47) | Chronic (n=129), n (%) | Accelerated (n=13), n (%) | Blast crisis (n=11), n (%) | |
|
| ||||||||||
| CYP3A5 * 3 | ||||||||||
| Homozygous wild type (AA) | 1 (0.98) | 0 | 1 (1.4) | 1 (1.2) | 1 (5.2)# | 0 | 0 | 1 (0.8) | 0 | 0 |
| Heterozygous (AG) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Homozygous mutant (GG) | 101 (99.02) | 51 (100) | 73 (98.6) | 78 (98.8) | 18 (94.8)# | 87 (100)# | 47 (100)# | 128 (99.2) | 13 (100) | 11 (100) |
| CYP3A4 * 18 | ||||||||||
|
| ||||||||||
| Homozygous wild type (TT) | 100 (98.04) | 50 (98.04) | 72 (97.2) | 78 (98.8) | 19 (100)δ | 87 (100)δ | 44 (93.6)δ | 126 (97.7) | 13 (100) | 11 (100) |
| Heterozygous (TC) | 2 (1.96) | 1 (1.96) | 2 (2.8) | 1 (1.2) | 0 | 0 | 3 (6.4)δ | 3 (2.3) | 0 | 0 |
| Homozygous mutant (CC) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CYP2B6 * 6 | ||||||||||
|
| ||||||||||
| Homozygous wild type (GG) | 49 (48) | 25 (49) | 41 (55.4) | 33 (41.7) | 7 (36.8) | 43 (49.4) | 24 (51.1) | 63 (49) | 5 (35.7) | 6 (54.6) |
| Heterozygous (GT) | 37 (36.4) | 17 (33.3) | 22 (29.7) | 32 (40.5) | 9 (47.4) | 29 (33.3) | 16 (34) | 45 (340) | 7 (50) | 2 (18.2) |
| Homozygous mutant (TT) | 16 (15.6) | 9 (17.7) | 11 (14.9) | 14 (17.8) | 3 (15.8) | 15 (17.3) | 7 (14.9) | 21 (17) | 1 (14) | 3 (27.3) |
#P<0.05 for CYP3A5*3; δP<0.05 for CYP3A4*18 polymorphism, respectively. CML, chronic myeloid leukemia